Health

DEBIOPHARM REINFORCES THE BOND BETWEEN SWISS AND JAPANESE CANCER RESEARCH WITH THE 2022 JCA MAUVERNAY AWARD CEREMONY

Debiopharm awards the winning scientists for the JCA (Japanese Cancer Association) Award for innovative, disruptive, and translational oncology research   Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company, today announced the two winners of JCA Mauvernay Award for breakthrough Japanese oncology research projects in 2 categories: Innovative and/or Disruptive Research – Dr. Akihide Yoshimi and for Translational…

thaipr.net

3 ต.ค. 65

ABILITY DIABETES GLOBAL – A Landmark RCT in the field of PCI for patients with DM, completes Enrolment

ABILITY DIABETES-GLOBAL (ADG), is the World’s largest Randomized Controlled Trial (RCT) for patients with DM (Diabetes Mellitus), comparing head-to-head the Sirolimus eluting stent , Abluminus DES+ (Concept Medical Inc.) with the XIENCE family of DES (Abbott Cardiovascular). Diabetes has been the Achilles heel for any vascular interventional procedures and there is a clinical need for adequately […]

thaipr.net

30 ก.ย. 65

Pharming Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib

The FDA has assigned a PDUFA goal date of March 29, 2023 for the NDA submission based on randomized-controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary immunodeficiency Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) announces that the US Food and Drug Administration (FDA) […]

thaipr.net

30 ก.ย. 65
1 … 68 69 70 71 72 … 139

Copyright © 2026 Dataxet Limited (บริษัท ดาต้าเซ็ต จำกัด). All Rights Reserved.